We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+55.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7B
AUM Growth
+$1.73B
Cap. Flow
-$5.41M
Cap. Flow %
-0.08%
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$111M
2
BMY icon
Bristol-Myers Squibb
BMY
+$97.4M
3
GKOS icon
Glaukos
GKOS
+$94.2M
4
DHR icon
Danaher
DHR
+$91.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.7M

Top Sells

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$96.3M
2
WMGI
Wright Medical Group Inc
WMGI
+$79.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$66.9M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$55.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.81%
2 Financials 1.53%
3 Miscellaneous 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
126
DELISTED
Otonomy, Inc.
OTIC
$1.34M 0.02%
+350,700
New +$857K
SPRO icon
127
Spero Therapeutics
SPRO
$65.8M
$1.27M 0.02%
131,653
-9,056
-6% -$97.7K
STRO icon
128
Sutro Biopharma
STRO
$275M
$1.15M 0.02%
+10,480
New +$1.08M
RGNX icon
129
Regenxbio
RGNX
$525M
$1.1M 0.02%
+26,800
New +$1.06M
BMY.RT
130
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.05M 0.02%
+350,000
New +$910K
MBIO icon
131
Mustang Bio
MBIO
$3.82M
$1.03M 0.01%
+336
New +$769K
RUBY
132
PUT
DELISTED
Rubius Therapeutics, Inc
RUBY
$950K 0.01%
100,000
– –
LRMR icon
133
Larimar Therapeutics
LRMR
$406M
$911K 0.01%
+68,417
New +$654K
APTX
134
DELISTED
Aptinyx Inc. Common Stock
APTX
$489K 0.01%
+143,000
New +$492K
BLRX
135
BioLineRX
BLRX
$12.2M
$156K ﹤0.01%
1,731
– –
XYLO
136
DELISTED
Xylo Technologies
XYLO
$26K ﹤0.01%
375
– –
APLS
137
DELISTED
Apellis Pharmaceuticals
APLS
– –
-623,859
Closed -$15M
CVM icon
138
PUT
CEL-SCI Corp
CVM
$26M
– –
-4,167
Closed -$1.12M
EHTH icon
139
CALL
eHealth
EHTH
$28.5M
– –
-100,000
Closed -$6.68M
IBB icon
140
PUT
iShares Biotechnology ETF
IBB
$10.3B
– –
-200,000
Closed -$19.9M
PBYI icon
141
CALL
Puma Biotechnology
PBYI
$477M
– –
-150,000
Closed -$1.61M
PBYI icon
142
Puma Biotechnology
PBYI
$477M
– –
-636,600
Closed -$6.85M
RARE icon
143
Ultragenyx Pharmaceutical
RARE
$1.29B
– –
-834,313
Closed -$35.7M
SIBN icon
144
SI-BONE Inc
SIBN
$831M
– –
-422,000
Closed -$7.46M
SRPT icon
145
CALL
Sarepta Therapeutics
SRPT
$2.19B
– –
-50,000
Closed -$3.77M
TAK icon
146
Takeda Pharmaceutical
TAK
$59.7B
– –
-750,000
Closed -$12.9M
YARW
147
Yarrow Bioscience
YARW
$68.1M
– –
-184
Closed -$2.97M
RETA
148
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-150,000
Closed -$12M
CNST
149
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-835,842
Closed -$5.4M
WMGI
150
DELISTED
Wright Medical Group Inc
WMGI
– –
-3,837,250
Closed -$79.2M
3 4 5
6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2019 Portfolio in Review

As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
  • OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
  • OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
  • OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
  • OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
  • OrbiMed opened 40 new positions and closed 20 in Q4 2019.
  • OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.